World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
78226
World Ranking
7776
National Ranking
297

Malcolm J. Moore publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Malcolm J. Moore sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 420 publications — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Malcolm J. Moore D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Malcolm J. Moore sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 101 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Malcolm J. Moore is affiliated with the Princess Margaret Cancer Centre in Canada. Their research primarily spans the fields of medicine and biochemistry, genetics, and molecular biology, with a strong focus on oncology and cancer-related studies.

Their work encompasses several subfields including oncology, cancer research, economics and econometrics, surgery, and pulmonary and respiratory medicine. The specific research topics covered in their publications include pancreatic and hepatic oncology, cancer genomics and diagnostics, colorectal cancer treatments and studies, economic and financial impacts of cancer, health systems and economic evaluations related to quality of life, genetic factors in colorectal cancer, and advances in neuroendocrine tumor research.

The scientist has contributed to multiple papers, with notable recent publications including:

  • Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (2023, Journal of Clinical Oncology)
  • Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial (2023, Journal of Clinical Oncology)
  • Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial (2022, Journal of Clinical Oncology)
  • Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial (2023, JCO Oncology Practice)
  • Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study (2023, Journal of Clinical Oncology)

Their frequent coauthors include Jennifer J. Knox, Robert C. Grant, Steven Gallinger, Anna Dodd, and Grainne M. O'Kane. These collaborations point to a network engaged in clinical oncology and cancer therapeutic research.

Malcolm J. Moore's research has been published predominantly in the following venues:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • World Journal of Gastroenterology
  • Cancer Medicine

Best Publications

  • Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

    H A Burris;M J Moore;J Andersen;M R Green

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Malcolm J. Moore;David Goldstein;John Hamm;Arie Figer

  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

    Christos S Karapetis;Shirin Khambata-Ford;Derek J Jonker;Chris J O'Callaghan

  • Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

    Leonard B. Saltz;John V. Cox;Charles Blanke;Lee S. Rosen

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

    Christine M. Ribic;Daniel J. Sargent;Malcolm J. Moore;Malcolm J. Moore;Stephen N. Thibodeau

  • Cetuximab for the Treatment of Colorectal Cancer

    Derek J Jonker;Chris J O'Callaghan;Christos S Karapetis;John R Zalcberg

  • Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

    I. F. Tannock;D. Osoba;M. R. Stockler;D. S. Ernst

  • Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

    Camilla Zimmermann;Nadia Swami;Monika Krzyzanowska;Monika Krzyzanowska;Breffni Hannon;Breffni Hannon

  • Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

    Hans von der Maase;Lisa Sengelov;James T. Roberts;Sergio Ricci

  • Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

    Daniel J. Sargent;Silvia Marsoni;Genevieve Monges;Stephen N. Thibodeau

  • Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

    John P. Neoptolemos;Deborah D. Stocken;Claudio Bassi;Paula Ghaneh

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • Advanced pancreatic carcinoma: current treatment and future challenges.

    Anastasios Stathis;Malcolm J. Moore

  • Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

    Eric Van Cutsem;Walter L. Vervenne;Jaafar Bennouna;Yves Humblet

  • A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

    M. L. Rothenberg;M. J. Moore;M. C. Cripps;J. S. Andersen

  • Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

    Emmanuel Mitry;Anthony L.A. Fields;Harry Bleiberg;Roberto Labianca

  • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Aimery de Gramont;Eric Van Cutsem;Hans Joachim Schmoll;Josep Tabernero

  • Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients with Bladder Cancer

    H. von der Maase;L. Sengelov;J.T. Roberts;S. Ricci

Frequent Co-Authors

Lillian L. Siu
Lillian L. Siu University of Toronto
David W. Hedley
David W. Hedley Princess Margaret Cancer Centre
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Padraig Warde
Padraig Warde Princess Margaret Cancer Centre
Dongsheng Tu
Dongsheng Tu Queen's University
Michael A.S. Jewett
Michael A.S. Jewett University of Toronto
Gary Rodin
Gary Rodin Princess Margaret Cancer Centre
John R. Zalcberg
John R. Zalcberg Monash University
Steven Gallinger
Steven Gallinger Ontario Institute for Cancer Research
Camilla Zimmermann
Camilla Zimmermann University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to a variety of related healthcare degrees and career pathways you can pursue online. For registered nurses aiming to advance their careers, the adn to fnp pathway allows experienced RNs with an associate degree to work toward becoming a Family Nurse Practitioner through flexible bridge programs.

If your interests include preventative health or wellness, an online nutrition degree can help you build expertise in dietetics and health education—a growing area in medicine that offers diverse job opportunities.

For those who wish to step into healthcare administration, consider enrolling in one of the best mha programs. These CAHME-accredited online Master of Health Administration programs prepare graduates for leadership roles in hospitals, clinics, or public health sectors.

Additionally, working nurses may be interested in an rn to bsn online without clinicals program, which offers a convenient way to further nursing education without needing on-site clinical training. Each of these options provides flexible, reputable ways to advance in today’s healthcare landscape.

Best Scientists Citing Malcolm J. Moore

Trending Scientists

Recently Published Articles